A team of researchers from the University of Colorado School of Medicine recently published a paper that provides new insights into the role of hypoxia or hypoxia in the development of cancer. Dr. Joaquin Espinosa, a member of the CU Cancer Center, is a senior researcher on the paper, and he hopes this will help lead to more targeted cancer treatments.
Their papers were published this month in the journal Nature Communications by Espinosa and other teams-Dr. Zdenek Andrysik; Dr. Heather Bender; and Dr. Matthew Galbraith used state-of-the-art genomic technology to map the response of cancer cells to hypoxia in unprecedented detail Atlas, leading to new discoveries about how hypoxia-inducible factor (HIF) affects cancer cell and tumor growth.
The hypoxia debate
The adaptability of cells to hypoxia is one of the fundamental aspects of cancer biology, especially in solid tumors.
Galbraith explained: “Most tumors cannot grow unless they can find a way to induce the formation of new blood vessels to provide them with oxygen and other nutrients.” “So what happens inside solid tumors is that they are in the new There are intermittent periods of hypoxia between the rounds of blood vessel formation."
Past studies have focused on the long-term effects of hypoxia on tumor growth, which are usually characterized as carcinogenic or cancer-promoting. However, other studies have shown that factors that perceive hypoxia (called hypoxia-inducible factors) or HIF can act as tumor growth inhibitors in some cases. To move the field beyond this controversy, Espinosa and colleagues investigated the immediate acute response to hypoxia.
Comments
Post a Comment